On December 31, 2019, pneumonia due to the severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2, formerly known as 2019-nCoV) appeared to Wuhan, China, and COVID-19 is an infectious disease caused by SARS. CoV-2. SARS-CoV-2 is a new strain of coronavirus that has not been previously identified in humans. Until April 18, 2020, 2275783 were confirmed and 156104 deaths worldwide reported. This paper presents an overview of the findings that scientists have realized so far. In this study articles indexed in Embase, Elsevier, PubMed, Google Scholar and using keywords SARS-CoV-2, COVID-19, Coronavirus 2019 and nCoV-2019 were used. The World Health Organization and the Centers for Disease Control and Prevention used the world's most reputable websites to obtain the latest COVID-19 disease statistics. In the initial search, 500 articles were extracted and 55 articles were selected after duplication and evaluation of title and abstract. The results show that the mortality rate of the virus in the elderly and people with underlying diseases is significantly higher than in the healthy ones. High-risk groups for the disease include cardiovascular disease, diabetes, chronic respiratory disease, and hypertension, respectively. The novel coronavirus Pandemic is more widespread in humans compared to previous coronaviruses, which indicates the extremely high prevalence of the virus. No vaccine or cure has been found for the virus so far, but supportive treatments and early diagnosis are effective in the treatment process, and there are many treatments around the world for the treatment of COVID-19.

Background: Guillain-Barré,Syndrome (GBS) is an autoimmune disease that may occur after infections. As Coronavirus Disease 2019 (COVID-19) may bring about GBS, it is important to assess the effect of the COVID-19 Pandemic on this disease Objectives: This study aimed to compare the distribution and characteristics of GBS during and before the COVID-19 Pandemic in an academic referral hospital in the north of Iran. Materials & Methods: This retrospective study assessed GBS distribution and characteristics during the COVID-19 Pandemic period (from March 2020 to the end of February 2021) and before the Pandemic (from March 2019 to the end of February 2020) on 5340 patients referred to the Neurology Ward of Poursina Hospital of Guilan Province, in Iran. Results: There was no significant difference between GBS distribution during (0. 03%) and before (0. 04%) the COVID-19 Pandemic (P=0. 413). There were also no differences between the two periods regarding the gender (P=0. 659) and age (P=0. 417) of the patients. The most common subtype of GBS during the COVID-19 Pandemic was Acute Motor and Sensory Axonal Neuropathy (AMSAN) (71. 4%). In both periods, the most common type of treatment was intravenous administration of immune globulin. There was no significant difference between the two periods (P=0. 838) regarding the patients’,treatment response. Conclusion: The distribution of GBS, its subtypes, type of treatment, and response to treatment were not different between the two study periods.